Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTX-301 in Relapsed or Refractory MDS and AML
NCT04167917Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2021
- Primary completion
- Apr 2025
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTX-301 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Alabama at Birmingham. Primary endpoint: Incidence of treatment related adverse events and dose-limiting toxicities at 3 years. Started Jan 2021; status: completed.
02
Drugs
NTX-301
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04167917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167917.